Mike is pursuing his J.D. at Boston College Law School. During his first year at BC, Mike wrote an article for the Boston College Intellectual Property and Technology Forum, focusing on the patent interference proceeding and dispute over patent rights to the recently discovered genetic engineering technology CRISPR-Cas9. He will be serving as an Editor for the Forum in the upcoming school year. While pursuing a degree in Biology, Mike worked as a research assistant on multiple projects, including a study within the Department of Pharmacology at Yale Medical School focused on understanding the biochemical mechanisms underlying the development and progression of the neurodegenerative disease Spinocerebellar Ataxia-13.
By Stephen F.W. Ball, Jr. Motions to dismiss, also called 12(b)(6) motions, have been used to eviscerate patent rights on the basis that a patent is allegedly directed to an “abstract concept” and thus lacks [Read More…]
WHIPgroup obtained another patent allowance using the After Final Consideration Pilot (AFCP) Program. In U.S. Application No. 15/239,469 directed to an eccentric well pipe, a Final Office Action rejected pending claims for obviousness. WHIPgroup attorneys [Read More…]
WHIPgroup attorneys were successful in using the Pre-Appeal Brief Review program to overcome a final rejection. During prosecution, the USPTO rejected claims directed to a method for actively damping oscillations in a compression process as [Read More…]